NASDAQ:IMMU - Immunomedics Stock Price, Price Target & More

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

Immunomedics, Inc. (NASDAQ:IMMU) announced its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.06. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to analysts' expectations of $4.27 million. The business's revenue was down 61.5% compared to the same quarter last year. View Immunomedics' Earnings History.

2 brokerages have issued 1-year target prices for Immunomedics' stock. Their predictions range from $15.00 to $27.00. On average, they anticipate Immunomedics' share price to reach $21.00 in the next twelve months. View Analyst Ratings for Immunomedics.

Immunomedics saw a increase in short interest in May. As of May 15th, there was short interest totalling 30,336,254 shares, an increase of 6.7% from the April 30th total of 28,420,435 shares. Based on an average daily trading volume, of 1,803,458 shares, the days-to-cover ratio is presently 16.8 days. Approximately 20.5% of the shares of the company are sold short.

Some companies that are related to Immunomedics include Ipsen (IPSEY), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), New England Nuclear (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML) and Akers Biosciences (AKER).

Media coverage about IMMU stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immunomedics earned a media sentiment score of 0.16 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.58 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Immunomedics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.45%), Acuta Capital Partners LLC (3.50%), Palo Alto Investors LP (2.87%), Victory Capital Management Inc. (1.13%), Northern Trust Corp (0.76%) and Nexthera Capital LP (0.65%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

IMMU stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, JPMorgan Chase & Co., Lyon Street Capital LLC, UBS Group AG, Jane Street Group LLC, Iguana Healthcare Management LLC, Highland Capital Management LP and BlackRock Inc.. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison, Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.

IMMU stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Nexthera Capital LP, Massachusetts Financial Services Co. MA, Rock Springs Capital Management LP, Sphera Funds Management LTD., University of Notre Dame DU Lac, Royal Bank of Canada and DekaBank Deutsche Girozentrale. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IMMU stock can currently be purchased for approximately $22.78.

Immunomedics has a market capitalization of $3.81 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]